# Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

> **NCT01565746** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 19 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT01565746
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-10
- **Final completion:** 2016-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565746, "Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01565746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*